BIORETEC OY |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.6 EUR | -1.14% |
|
-5.45% | +8.33% |
| Apr. 05 | Bioretec Oy Announces Pekka Simula Not Available for Re-Election to Board of Directors | CI |
| Mar. 22 | Finland's Bioretec Gets US Patent Allowance for Magnesium Alloy Composition | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Capitalization 1 | 19.83 | 46.89 | 53.49 | 53.49 | - |
| Enterprise Value (EV) 1 | 19.83 | 46.89 | 53.49 | 51.89 | 53.89 |
| P/E ratio | -3.27 x | -14.1 x | -13.8 x | -17.5 x | -40.5 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 15.9 x | 13.7 x | 9.07 x | 4.95 x |
| EV / Revenue | - | 15.9 x | 13.7 x | 8.79 x | 4.99 x |
| EV / EBITDA | - | -22.2 x | -18.9 x | -18.2 x | -98 x |
| EV / FCF | - | -17.9 x | -14 x | -15.5 x | -29.1 x |
| FCF Yield | - | -5.59% | -7.13% | -6.46% | -3.43% |
| Price to Book | - | 24.5 x | 7.97 x | 12.5 x | 18.1 x |
| Nbr of stocks (in thousands) | 14,112 | 19,537 | 20,337 | 20,337 | - |
| Reference price 2 | 1.405 | 2.400 | 2.630 | 2.630 | 2.630 |
| Announcement Date | 2/17/22 | 2/17/23 | 2/16/24 | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net sales 1 | - | 2.942 | 3.906 | 5.9 | 10.8 |
| EBITDA 1 | - | -2.112 | -2.833 | -2.85 | -0.55 |
| EBIT 1 | - | -2.292 | -3.034 | -3.15 | -1.15 |
| Operating Margin | - | -77.91% | -77.68% | -53.39% | -10.65% |
| Earnings before Tax (EBT) 1 | - | -2.415 | -3.788 | -3.3 | -1.35 |
| Net income 1 | -6.017 | -2.416 | -3.789 | -3.3 | -1.35 |
| Net margin | - | -82.12% | -97% | -55.93% | -12.5% |
| EPS 2 | -0.4300 | -0.1700 | -0.1900 | -0.1500 | -0.0650 |
| Free Cash Flow 1 | - | -2.62 | -3.4 | -3.35 | -1.85 |
| FCF margin | - | -89.06% | -85% | -56.78% | -17.13% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/17/22 | 2/17/23 | 2/16/24 | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 0.4 |
| Net Cash position 1 | - | - | 5.8 | 1.6 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.7273 x |
| Free Cash Flow 1 | - | -2.62 | -3.4 | -3.35 | -1.85 |
| ROE (net income / shareholders' equity) | - | -77.2% | -68.8% | -51.1% | -40.7% |
| ROA (Net income/ Total Assets) | - | - | - | - | - |
| Assets 1 | - | - | - | - | - |
| Book Value Per Share 2 | - | 0.1000 | 0.3300 | 0.2100 | 0.1500 |
| Cash Flow per Share 2 | - | -0.1200 | -0.1200 | -0.1100 | -0.0500 |
| Capex 1 | - | 0.26 | 0.35 | 0.55 | 0.75 |
| Capex / Sales | - | 8.85% | 8.75% | 9.32% | 6.94% |
| Announcement Date | 2/17/22 | 2/17/23 | 2/16/24 | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
2.63
EUR
Average target price
3.75
EUR
Spread / Average Target
+42.59%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +8.33% | 57.31M | |
| +72.92% | 12.36B | |
| -19.68% | 7.83B | |
| +16.20% | 7.21B | |
| +4.86% | 5.97B | |
| +7.49% | 5.14B | |
| +23.97% | 4.43B | |
| -18.81% | 3.9B | |
| -41.54% | 2.2B | |
| +1.49% | 2.02B |
- Stock Market
- Equities
- BRETEC Stock
- Financials Bioretec Oy
